U.S. markets closed

Telix Pharmaceuticals Limited (TLPPF)

Other OTC - Other OTC Delayed Price. Currency in USD
4.9800+0.0270 (+0.55%)
At close: 12:20PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.9530
BidN/A x N/A
AskN/A x N/A
Day's Range4.9800 - 4.9800
52 Week Range2.6900 - 6.3800
Avg. Volume1,606
Market Cap1.666B
Beta (5Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)-0.1980
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TLPPF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Daily – Vickers Top Buyers & Sellers for 10/14/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • PR Newswire

    Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand

    Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an important development in radioisotope production.

  • PR Newswire

    First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

    Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM).

  • PR Newswire

    Telix Acquires Optimal Tracers

    Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials.